The safety of alpha fetoprotein in diagnosis of hepatocellular carcinoma in patients with type 2 diabetes mellitus

Aim: Diabetes mellitus is closely associated with many types of cancer including hepatocellular carcinoma (HCC). Alpha feto proteinis still used as a biomarker for HCC worldwide but relation between type 2 diabetes mellitus (T2DM) and AFP is unclear. We aimed toinvestigate relations between AFP, T2DM and metabolic markers in this study.Material and Methods: 208 HCC patients were enrolled to study. 50 patients had T2DM (T2DM+HCC) and 158 patients were nondiabetic (NDM+HCC). 50 healthy people enrolled to the study as control group. Serum AFP levels were compared between healthycontrol group, T2DM+HCC group and NDM+HCC group. Serum AFP levels were compared with age, BMI, HgbA1c, fasting plasmaglucose level (FPG), serum insulin level and insulin resistance (HOMA-IR).Results: AFP levels were higher in T2DM + HCC group patients according to healthy control group (p

PDF

___

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:359-86.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27.
3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42:206-14.
4. Group IDFDA. Update of mortality attributable to diabetes for the IDF diabetes atlas: estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5.
5. Ali Kamkar MM, Ahmad R, Alsmadi O, et al. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord 2014;22:1-57.
6. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
7. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
8. Møller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30:344-50.
9. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
10. Vora SR, Zheng H, Stadler ZK, et al. Serum alphafetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14:717-25.
11. Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res 2013;19:3944-54.
12. Liu CY, Feng GS. NCOA5, a molecular link between type 2 diabetes and liver cancer, Hepatobiliary Surg Nutr 2014;3:106-8.
13. Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer 2005;92:2076-83.
14. Chen L, Li H, Gu L, et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies, Medicine Baltim 2015;94:1055.
15. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review, World J. Gastroenterol 2015; 21:6026-31.
16. Chen HF, Liu MD, Chen P, et al. Risks of breast and endometrial cancer in women with diabetes: A population-based cohort study, PLoS ONE 2013;8: 67420 .
17. Mandeep KS, Bhrigu KD, Sandeep C, et al. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.Biomed Pharmacother 2018;106:991-1002.
18. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-9.
19. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systemic review of epidemiology evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
20. Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-62.
21. Yang S, Liu L, Luo Y, et al. Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2018;143:239-44.
22. Turgutalp K, Ozhan O, Helvacı I, et al. Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study. Clin Chem Lab Med 2013;51:889-95.
23. El-Serag HB, Kanwal F. Obesity and hepatocellular carcinoma: hype and reality. Hepatology 2014; 60:779-81.
24. Saunders D, Seidel D, Allison M, et al. Systematic review: the association between obesity and hepatocellular carcinoma-epidemiological evidence. Aliment Pharmacol Ther 2010;31:1051-63.
25. Elsayed EY, Mosalam NA, Mohamed NR. Resistin and Insulin Resistance: A Link Between Inflammation and Hepatocarcinogenesis. Asian Pac J Cancer Prev 2015; 16:7139-42.
26. Stepanova M, Lam B, Younossi Y, et al. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 2012;19:341-5.
27. Desouky DE, Kasemy Z, Abdel-Hamid AE, et al. Insulin resistance and prediabetes in hepatitis C virus patients. Am J Med Sci 2015;350:77-80.
28. Mark WD, Jacob G. Molecular mechanisms of insulin resistance in chronic hepatitis C World J Gastroenterol 2009;15:4356-64.